Flamel Technologies SA is a specialty pharmaceutical company with a long history of expertise in drug delivery. The acquisition of Éclat Pharmaceuticals LLC has created a more vertically integrated company, benefiting from greater development and commercial expertise, best in class drug delivery platforms and potential value creating catalysts.
Drug Delivery Platforms
Controlled release of oral drugs.
Controlled release oral liquid drugs.
Tamper-resistant controlled release formulations of narcotics and other drugs prone to abuse.
Controlled release of injected biologics and small molecules drugs.
Flamel Technologies currently markets Bloxiverz and Vazculep (FDA-approved products), and develops internally products using the Unapproved Marketed Drug strategy and products based on its drug delivery platforms, and products with partners.
As a publicly-held company, Flamel Technologies strives to use its technologies to create extraordinary shareholder value.